Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases. However, the precise mechanism by which PCSK9 regulates the internalization and lysosomal degradation of LDLR is unknown. Recently, we identified adenylyl cyclase-associated protein 1 (CAP1) as a receptor for human resistin whose globular C-terminus is structurally similar to the C-terminal cysteine-rich domain (CRD) of PCSK9. Herein, we investigated the role of CAP1 in PCSK9-mediated lysosomal degradation of LDLR and plasma LDL cholesterol (LDL-C) levels. Methods and results: The direct binding between PCSK9 and CAP1 was confirmed by immunoprecipitation assay, far-western blot, biomolecular fluorescence complementation, and surface plasmon resonance assay. Fine mapping revealed that the CRD of PCSK9 binds with the Src homology 3 binding domain (SH3BD) of CAP1. Two loss-of-function polymorphisms found in human PCSK9 (S668R and G670E in CRD) were attributed to a defective interaction with CAP1. siRNA against CAP1 reduced the PCSK9-mediated degradation of LDLR in vitro. We generated CAP1 knock-out mice and found that the viable heterozygous CAP1 knock-out mice had higher protein levels of LDLR and lower LDL-C levels in the liver and plasma, respectively, than the control mice. Mechanistic analysis revealed that PCSK9-induced endocytosis and lysosomal degradation of LDLR were mediated by caveolin but not by clathrin, and they were dependent on binding between CAP1 and caveolin-1. Conclusion: We identified CAP1 as a new binding partner of PCSK9 and a key mediator of caveolae-dependent endocytosis and lysosomal degradation of LDLR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Self-citationCardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596 · cited 3×
“the C-terminal cysteinerich domain (CRD), is suspected to interact with a putative membrane-bound protein that escorts the protein complex towards lysosomal degradation.(1) Recently, PCSK9-CRD has been reported to have structural homology with the human resistin C-terminal domain homotrimer,(5) which is a pro-inflamma…”
BackgroundThe cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., & Seidah, N. G. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00562.x · Cited by 248
The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH
Maurer, M. E., & Cooper, J. A. (2006) · Journal of Cell Science · doi:10.1242/jcs.03217 · Cited by 195
Biochemical analysis of distinct Rab5- and Rab11-positive endosomes along the transferrin pathway
Trischler, M., Stoorvogel, W., & Ullrich, O. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.24.4773 · Cited by 162
Garuti, R., Jones, C., Li, W.-P., Michaely, P., Herz, J., Gerard, R. D., Cohen, J. C., & Hobbs, H. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509394200 · Cited by 91 · cited 1×
“During the process, adaptor molecules, such as ARH and DAB2, mediate clathrin-dependent endocytosis.(27,28) While PCSK9 also promotes clathrin-dependent endocytosis, it does not lead to lysosomal degradation of LDLR (Figure 4G and H).”
Background
Cited by
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xia, X.-D., Peng, Z.-S., Gu, H.-M., Wang, M., Wang, G.-Q., & Zhang, D.-W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.764038 · Cited by 125
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Punch, E., Klein, J., Diaba‐Nuhoho, P., Morawietz, H., & Garelnabi, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023328 · Cited by 101
Expanding biology of PCSK9: roles in atherosclerosis and beyond
Seidah, N. G., & Garçon, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01057-z · Cited by 76
Metadata
- Authors
- Jang, H.-D., Lee, S. E., Yang, J., Lee, H.-C., Shin, D., Lee, H., Lee, J., Jin, S., Kim, S., Lee, S. J., You, J., Park, H.-W., Nam, K.-Y., Lee, S.-H., Park, S. W., Kim, J.-S., Kim, S.-Y., Kwon, Y.-W., Kwak, S. H., Yang, H.-M., & Kim, H.-S.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-08-16
- Volume
- 41
- Issue
- 2
- Pages
- 239-252
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2981286566
- Cited by
- 99
- References
- 10
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. https://app.cochat.ai/papers/10.1093/eurheartj/ehz566
- The paper
- Jang, H.-D., Lee, S. E., Yang, J., Lee, H.-C., Shin, D., Lee, H., Lee, J., Jin, S., Kim, S., Lee, S. J., You, J., Park, H.-W., Nam, K.-Y., Lee, S.-H., Park, S. W., Kim, J.-S., Kim, S.-Y., Kwon, Y.-W., Kwak, S. H., . . . Kim, H.-S. (2020). Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz566
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.